174 related articles for article (PubMed ID: 14603341)
1. Diffuse large B-cell lymphomas with plasmablastic/plasmacytoid features are associated with TP53 deletions and poor clinical outcome.
Simonitsch-Klupp I; Hauser I; Ott G; Drach J; Ackermann J; Kaufmann J; Weltermann A; Greinix HT; Skrabs C; Dittrich C; Lutz D; Pötter R; Mannhalter C; Lechner K; Chott A; Jaeger U
Leukemia; 2004 Jan; 18(1):146-55. PubMed ID: 14603341
[TBL] [Abstract][Full Text] [Related]
2. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma.
Colomo L; López-Guillermo A; Perales M; Rives S; Martínez A; Bosch F; Colomer D; Falini B; Montserrat E; Campo E
Blood; 2003 Jan; 101(1):78-84. PubMed ID: 12393466
[TBL] [Abstract][Full Text] [Related]
3. [Clinical characteristics and prognosis of diffuse large B-cell lymphoma].
Yang BY; Yong WB; Zhu J; Zheng W; Zhang YT; Wang XP; Meng SN
Zhonghua Zhong Liu Za Zhi; 2005 Mar; 27(3):174-6. PubMed ID: 15946571
[TBL] [Abstract][Full Text] [Related]
4. Diffuse large B-cell lymphoma: clinical and biological characterization and outcome according to the nodal or extranodal primary origin.
López-Guillermo A; Colomo L; Jiménez M; Bosch F; Villamor N; Arenillas L; Muntañola A; Montoto S; Giné E; Colomer D; Beà S; Campo E; Montserrat E
J Clin Oncol; 2005 Apr; 23(12):2797-804. PubMed ID: 15728226
[TBL] [Abstract][Full Text] [Related]
5. Diffuse large B-cell lymphoma: a clinicopathologic analysis of 444 cases classified according to the updated Kiel classification.
Diebold J; Anderson JR; Armitage JO; Connors JM; Maclennan KA; Müller-Hermelink HK; Nathwani BN; Ullrich F; Weisenburger DD
Leuk Lymphoma; 2002 Jan; 43(1):97-104. PubMed ID: 11908742
[TBL] [Abstract][Full Text] [Related]
6. Centroblastic and centroblastic/centrocytic lymphoma associated with a prominent epithelioid granulomatous response: a clinicopathologic study of 50 cases.
Kojima M; Nakamura S; Ichimura K; Suzuki R; Kagami Y; Kondo E; Motoori T; Hosomura Y; Oyama T; Itoh H; Ban S; Yoshida K; Ohno Y; Shimizu K; Masawa N; Sugihara S
Mod Pathol; 2002 Jul; 15(7):750-8. PubMed ID: 12118113
[TBL] [Abstract][Full Text] [Related]
7. Identification of outcome predictors in diffuse large B-cell lymphoma. Immunohistochemical profiling of homogeneously treated de novo tumors with nodal presentation on tissue micro-arrays.
Zinzani PL; Dirnhofer S; Sabattini E; Alinari L; Piccaluga PP; Stefoni V; Tani M; Musuraca G; Marchi E; Falini B; Baccarani M; Pileri SA
Haematologica; 2005 Mar; 90(3):341-7. PubMed ID: 15749666
[TBL] [Abstract][Full Text] [Related]
8. Lymphoma recurrence 5 years or later following diffuse large B-cell lymphoma: clinical characteristics and outcome.
Larouche JF; Berger F; Chassagne-Clément C; Ffrench M; Callet-Bauchu E; Sebban C; Ghesquières H; Broussais-Guillaumot F; Salles G; Coiffier B
J Clin Oncol; 2010 Apr; 28(12):2094-100. PubMed ID: 20308668
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathologic characteristics and outcome of diffuse large B-cell lymphomas presenting with an associated low-grade component at diagnosis.
Ghesquières H; Berger F; Felman P; Callet-Bauchu E; Bryon PA; Traverse-Glehen A; Thieblemont C; Baseggio L; Michallet AS; Coiffier B; Salles G
J Clin Oncol; 2006 Nov; 24(33):5234-41. PubMed ID: 17043351
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical expression of CD23 and CD40 may identify prognostically favorable subgroups of diffuse large B-cell lymphoma: a Nordic Lymphoma Group Study.
Linderoth J; Jerkeman M; Cavallin-Ståhl E; Kvaløy S; Torlakovic E;
Clin Cancer Res; 2003 Feb; 9(2):722-8. PubMed ID: 12576441
[TBL] [Abstract][Full Text] [Related]
11. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma.
Fu K; Weisenburger DD; Choi WW; Perry KD; Smith LM; Shi X; Hans CP; Greiner TC; Bierman PJ; Bociek RG; Armitage JO; Chan WC; Vose JM
J Clin Oncol; 2008 Oct; 26(28):4587-94. PubMed ID: 18662967
[TBL] [Abstract][Full Text] [Related]
12. The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study.
Thieblemont C; Briere J; Mounier N; Voelker HU; Cuccuini W; Hirchaud E; Rosenwald A; Jack A; Sundstrom C; Cogliatti S; Trougouboff P; Boudova L; Ysebaert L; Soulier J; Chevalier C; Bron D; Schmitz N; Gaulard P; Houlgatte R; Gisselbrecht C
J Clin Oncol; 2011 Nov; 29(31):4079-87. PubMed ID: 21947824
[TBL] [Abstract][Full Text] [Related]
13. Diffuse large B-cell non-Hodgkin lymphomas: the clinical relevance of histological subclassification.
Baars JW; de Jong D; Willemse EM; Gras L; Dalesio O; v Heerde P; Huygens PC; vd Lelie H; Kr vd Borne AE
Br J Cancer; 1999 Apr; 79(11-12):1770-6. PubMed ID: 10206291
[TBL] [Abstract][Full Text] [Related]
14. Diffuse large B-cell lymphomas with plasmablastic differentiation represent a heterogeneous group of disease entities.
Colomo L; Loong F; Rives S; Pittaluga S; Martínez A; López-Guillermo A; Ojanguren J; Romagosa V; Jaffe ES; Campo E
Am J Surg Pathol; 2004 Jun; 28(6):736-47. PubMed ID: 15166665
[TBL] [Abstract][Full Text] [Related]
15. Clinical relevance of immunophenotype in a retrospective comparative study of 297 peripheral T-cell lymphomas, unspecified, and 496 diffuse large B-cell lymphomas: experience of the Intergruppo Italiano Linformi.
Morabito F; Gallamini A; Stelitano C; Callea V; Guglielmi C; Neri S; Lazzaro A; Orsucci L; Ilariucci F; Sacchi S; Vitolo U; Federico M
Cancer; 2004 Oct; 101(7):1601-8. PubMed ID: 15378507
[TBL] [Abstract][Full Text] [Related]
16. Gastric and intestinal diffuse large B-cell lymphomas are clinically and immunophenotypically different. An immunohistochemical and clinical study.
Connor J; Ashton-Key M
Histopathology; 2007 Nov; 51(5):697-703. PubMed ID: 17927592
[TBL] [Abstract][Full Text] [Related]
17. International prognostic index-based outcomes for diffuse large B-cell lymphomas.
Wilder RB; Rodriguez MA; Medeiros LJ; Tucker SL; Ha CS; Romaguera JE; Pro B; Hess MA; Cabanillas F; Cox JD
Cancer; 2002 Jun; 94(12):3083-8. PubMed ID: 12115338
[TBL] [Abstract][Full Text] [Related]
18. Forkhead box protein P1 expression in mucosa-associated lymphoid tissue lymphomas predicts poor prognosis and transformation to diffuse large B-cell lymphoma.
Sagaert X; de Paepe P; Libbrecht L; Vanhentenrijk V; Verhoef G; Thomas J; Wlodarska I; De Wolf-Peeters C
J Clin Oncol; 2006 Jun; 24(16):2490-7. PubMed ID: 16636337
[TBL] [Abstract][Full Text] [Related]
19. ALK-positive diffuse large B-cell lymphoma: two more cases and a brief literature review.
Rudzki Z; Rucińska M; Jurczak W; Skotnicki AB; Maramorosz-Kurianowicz M; Mruk A; Piróg K; Utych G; Bodzioch P; Srebro-Stariczyk M; Włodarska I; Stachura J
Pol J Pathol; 2005; 56(1):37-45. PubMed ID: 15921012
[TBL] [Abstract][Full Text] [Related]
20. Orbital plasmablastic lymphoma--comparison of a newly reported entity with diffuse large B-cell lymphoma of the orbit.
Morley AM; Verity DH; Meligonis G; Rose GE
Orbit; 2009; 28(6):425-9. PubMed ID: 19929677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]